Patient outcomes after anti TNF-α drugs for Crohn’s disease

References

• Friedman S, Blumberg RS. Inflammatory bowel disease. In: Harrison’s Online. Kasper DL, Braunwald E, Fauci AS et al. (Eds). McGraw-Hill Health Professions Division, NY, USA (2008).
   Google Scholar
• Bernstein CN, Wajda A, Svenson LW et al. The epidemiology of inflammatory bowel disease in Canada: a population-based study. Am. J. Gastroenterol.101(7), 1559–1568 (2006).
   PubMed Web of Science ®Google Scholar
• Wong JLH. Inflammatory bowel disease. In: Clinic Handbook: Gastroenterology. Taylor & Francis, Abington, UK (2002).
   Google Scholar
• Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig. Dis. Sci.52(11), 2920–2925 (2007).
   PubMed Web of Science ®Google Scholar
• Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn’s disease: systematic review and meta-analysis of placebo-controlled trials. Clin. Infect. Dis.50(4), 473–480 (2010).
   PubMed Web of Science ®Google Scholar
• Doherty GA, Bennett GC, Cheifetz AS, Moss AC. Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn’s disease. Aliment. Pharmacol. Ther. (2010) (In Press).
   PubMedGoogle Scholar
• Rahimi R, Nikfar S, Rahimi F et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig. Dis. Sci.53(9), 2524–2531 (2008).
   PubMed Web of Science ®Google Scholar
• Gartlehner G, Hansen RA, Thieda P et al.Drug Class Review on Targeted Immune Modulators: Final Report. Oregon Health & Science University, OR, USA (2007).
   Google Scholar
• Remicade. In: Notices of Compliance. Health Canada, Canada (2001).
   Google Scholar
• Remicade [expansion of indication for Crohn’s disease]. In: Notices of Compliance. Health Canada, Canada (2004).
   Google Scholar
• Remicade [new indication – treatment of fistulizing Crohn’s disease, in adult patients, who have not responded despite a full and adequate course of therapy with conventional treatment]. In: Notices of Compliance. Health Canada, Canada (2005).
   Google Scholar
• Remicade [reduction of signs and symptoms and induction and maintenance of clinical remission in pediatric patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy]. In: Notices of Compliance. Health Canada, Canada (2006).
   Google Scholar
• Humira [new indication: reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy, including corticosteroid and/or immunosuppressants]. In: Notices of Compliance. Health Canada, Canada (2007).
   Google Scholar
• Assasi N, Blackhouse G, Xie F et al.Anti-TNF-α Drugs for Refractory Inflammatory Bowel Disease: Clinical – and Cost–Effectiveness Analyses. Canadian Agency for Drug and Technologies in Health, ON, Canada (2009).
   Google Scholar
• Jadad AR, Moore RA, Carroll D et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials17(1), 1–12 (1996).
   PubMedGoogle Scholar
• Wells GA, Shea B, O’Connell D et al.The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-analyses. Ottawa Health Research Institute, ON, Canada (2008).
   Google Scholar
• Sands BE, Abreu MT, Ferry GD et al. Design issues and outcomes in IBD clinical trials. Inflamm. Bowel Dis.11(Suppl. 1), S22–S28 (2005).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Hanauer SB et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology122(2), 512–530 (2002).
   PubMed Web of Science ®Google Scholar
• Principles of meta-analysis. Cochrane handbook for systematic reviews of interventions 5.0.0. In: The Cochrane Library. Higgins JPT, Green S (Eds). John Wiley & Sons Ltd, NJ, USA (2008)
   Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet359(9317), 1541–1549 (2002).
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van AG et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet371(9613), 660–667 (2008).
   PubMed Web of Science ®Google Scholar
• Targan SR, Hanauer SB, Van Deventer SJ et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N. Engl. J. Med.337(15), 1029–1035 (1997).
   PubMed Web of Science ®Google Scholar
• Lemann M, Mary JY, Duclos B et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology130(4), 1054–1061 (2006).
   PubMed Web of Science ®Google Scholar
• Present DH, Rutgeerts P, Targan S et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N. Engl. J. Med.340(18), 1398–1405 (1999).
   PubMed Web of Science ®Google Scholar
• Sands BE, Anderson FH, Bernstein CN et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N. Engl. J. Med.350(9), 876–885 (2004).
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, D’Haens G, Targan S et al. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology117(4), 761–769 (1999).
   PubMed Web of Science ®Google Scholar
• Mantzaris GJ, Ployzou P, Karagiannidis A et al. A prospective, randomized trial of infliximab (IFX) and azathioprine (AZA) for the induction and maintenance of remission of steroid-dependent Crohn’s disease (CD). Gastroenterology126(4 Suppl. 2), A54 (2004).
   Google Scholar
• Sandborn WJ, Hanauer SB, Rutgeerts P et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut56(9), 1232–1239 (2007).
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology130(2), 323–333 (2006).
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology132(1), 52–65 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Rutgeerts P, Enns R et al. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann. Intern. Med.146(12), 829–838 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer SB, Katz S et al. Etanercept for active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology121(5), 1088–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Laclotte C, Bigard MA. Adalimumab maintenance therapy for Crohn’s disease with intolerance or lost response to infliximab: an open-label study. Aliment. Pharmacol. Ther.25(6), 675–680 (2007).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Hanauer S, Loftus EV Jr et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am. J. Gastroenterol.99(10), 1984–1989 (2004).
   PubMed Web of Science ®Google Scholar
• Papadakis KA, Shaye OA, Vasiliauskas EA et al. Safety and efficacy of adalimumab (D2E7) in Crohn’s disease patients with an attenuated response to infliximab. Am. J. Gastroenterol.100(1), 75–79 (2005).
   PubMed Web of Science ®Google Scholar
• Hinojosa J, Gomollon F, Garcia S et al. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn’s disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment. Pharmacol. Ther.25(4), 409–418 (2007).
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Iida M, Motoya S et al. Therapeutic efficacy of infliximab on patients with short duration of Crohn’s disease: a Japanese multicenter survey. Dis.Colon Rectum51(6), 916–923 (2008).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF et al. Early Crohn’s disease shows high levels of remission to therapy with adalimumab: sub-analysis of charm. Gastroenterology132(4 Suppl. 2), A-147 (2007).
   Web of Science ®Google Scholar
• Rutgeerts P, Feagan BG, Lichtenstein GR et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology126(2), 402–413 (2004).
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology128(4), 862–869 (2005).
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panaccione R, Sandborn WJ et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn’s disease: results from the CHARM study. Gastroenterology135(5), 1493–1499 (2008).
   PubMed Web of Science ®Google Scholar
• Colombel Jf, Rutgeerts P, Yan S et al. Infliximab maintenance treatment results in lower hospitalization rate in Crohn’s disease patients. Gastroenterology122(4 Suppl. 1), A613 (2002).
   Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Stoinov S et al. Certolizumab pegol for the treatment of Crohn’s disease. N. Engl. J. Med.357(3), 228–238 (2007).
   PubMed Web of Science ®Google Scholar
• Schreiber S, Khaliq-Kareemi M, Lawrance IC et al. Maintenance therapy with certolizumab pegol for Crohn’s disease. N. Engl. J. Med.357(3), 239–250 (2007).
   PubMed Web of Science ®Google Scholar
• Lofberg R, Louis E, Reinisch W, Kron M, Camez A, Pollack P. Adalimumab effectiveness in TNF-αntagonist-naive patients and in infliximab nonresponders with Crohn’s disease: results from the CARE study. Am. J. Gastroenterol.103(Suppl.), 1069 (2008).
   Google Scholar
• Loftus E Jr, Feagan B, Colombel JF et al. Adalimumab treatment significantly reduces hospitalization risk for TNF-αntagonist-naive patients with Crohn’s disease. Am J Gastroenterol.103(Suppl.), (2008).
   Google Scholar
• Sandborn W, Rutgeerts P, Reinisch W et al. SONIC: a randomized, double-blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naive to immunomodulators and biologic therapy. Am. J. Gastroenterol.103, 1117 (2008).
   Web of Science ®Google Scholar
• Feagan B, McDonald JW, Panaccione R et al. A randomized trial of methotrexate in combination with infliximab for the treatment of crohn’s disease. Gastroenterology135(1), 294–295 (2008).
   Google Scholar
• Behm BW, Bickston SJ. Tumor necrosis factor-α antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev.(1), CD006893 (2008).
   Google Scholar
• D’Haens G, van DS, Van HR et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn’s disease: a European multicenter trial. Gastroenterology116(5), 1029–1034 (1999).
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Deltenre P, de SN, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol.6(6), 644–653 (2008).
   PubMed Web of Science ®Google Scholar
• Clark W, Raftery J, Song F et al. Systematic review and economic evaluation of the effectiveness of infliximab for the treatment of Crohn’s disease. Health Technol. Assess. (Winch. Eng.)7(3), 1–67 (2003).
   PubMedGoogle Scholar
• Bebb JR, Scott BB. Systematic review: how effective are the usual treatments for Crohn’s disease? Aliment. Pharmacol. Ther.20(2), 151–159 (2004).
   PubMed Web of Science ®Google Scholar
• Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials. Biomed. Pharmacother.61(1), 75–80 (2007).
   PubMed Web of Science ®Google Scholar
• Tine F, Rossi F, Sferrazza A et al. Meta-analysis: remission and response from control arms of randomized trials of biological therapies for active luminal Crohn’s disease. Aliment. Pharmacol. Ther.27(12), 1210–1223 (2008).
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Current directions in IBD therapy: what goals are feasible with biological modifiers? Gastroenterology135(5), 1442–1447 (2008).
   PubMed Web of Science ®Google Scholar
• Yun L, Hanauer S. Selecting appropriate anti-TNF agents in inflammatory bowel disease. Expert Rev. Gastroenterol. Hepatol.3(3), 235–248 (2009).
   PubMedGoogle Scholar
• Hanauer SB. Positioning biologic agents in the treatment of Crohn’s disease. Inflamm. Bowel Dis.15(10), 1570–1582 (2009).
   PubMed Web of Science ®Google Scholar
• Krygier DS, Ko HH, Bressler B. How to manage difficult Crohn’s disease: optimum delivery of anti-TNFs. Expert Rev. Gastroenterol. Hepatol.3(4), 407–415 (2009).
   PubMedGoogle Scholar
• Peyrin-Biroulet L, Desreumaux P, Sandborn WJ, Colombel JF. Crohn’s disease: beyond antagonists of tumour necrosis factor. Lancet372(9632), 67–81 (2008).
   PubMed Web of Science ®Google Scholar
• Bosani M, Ardizzone S, Porro GB. Biologic targeting in the treatment of inflammatory bowel diseases. Biologics3, 77–97 (2009).
   PubMedGoogle Scholar